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 27 
Abstract 28 
 29 
Adaptive autoimmunity is restrained by controlling population sizes and 30 
pathogenicity of harmful clones, while innate destruction is controlled at 31 
effector phase. We report here that deletion of Rptor in mouse 32 
hematopoietic stem/progenitor cells causes self-destructive innate 33 
immunity by massively increasing the population of previously 34 
uncharacterized innate myelolymphoblastoid effector cells (IMLECs). 35 
Mouse IMLECs are CD3-B220-NK1.1-Ter119- CD11clow/-CD115-F4/80low/-Gr-1- 36 
CD11b+, but surprisingly express high levels of PD-L1.  Although they 37 
morphologically resemble lymphocytes and actively produce transcripts 38 
from Immunoglobulin loci, IMLECs have non-rearranged Ig loci, are 39 
phenotypically distinguishable from all known lymphocytes, and have a 40 
gene signature that bridges lymphoid and myeloid leukocytes.  Rptor 41 
deletion unleashes differentiation of IMLECs from common myeloid 42 
progenitor cells by reducing expression of Myb. Importantly, IMLECs 43 
broadly overexpress pattern-recognition receptors and their expansion 44 
causes systemic inflammation in response to Toll-like receptor ligands in 45 
mice. Our data unveil a novel leukocyte population and an unrecognized 46 
role of Raptor/mTORC1 in innate immune tolerance. 47 
 48 
 3 
Introduction 49 
 50 
Autoreactive T and B lymphocytes are controlled by regulation of population 51 
sizes and pathogenicity through clonal deletion 1, clonal anergy 2 and regulatory 52 
T cells 3.  Through broadly-reactive pattern recognition receptors (PRRs) 4-5, 53 
innate immunity protects host against infections by both direct effector function 54 
and, indirectly, by induction of adaptive immunity 6-9.  Since innate immune 55 
responses triggered by host components can also cause fatal tissue damage10-11, 56 
it must be properly regulated to protect hosts against self-destruction. Although a 57 
number of mechanisms have been proposed to prevent self-destructive innate 58 
effector functions 12-16, it is less clear if population sizes of innate effectors are 59 
suppressed to limit self-destruction. 60 
 61 
The significance of protective self-tolerance mechanisms in adaptive immunity 62 
are revealed only when they have gone awry. For example, the significance of 63 
clonal deletion was elucidated when it was prevented by blocking either 64 
costimulation or antigen-expression in the thymus 17-18, while mice with Foxp3 65 
mutation informed us of the consequence of defective regulatory T cells 19-20. 66 
Since removal of the forbidden autoreactive T and B cells are achieved during T 67 
and B cell development 21-23, it is intriguing whether certain parallel mechanisms 68 
in innate immunity might also remain to be uncovered through genetic 69 
inactivation of key regulators in development of innate effector cells. 70 
 71 
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The hematopoietic system is among the best characterized of all tissue/systems 72 
in mammalians, with cell types and lineages clearly defined in the context of 73 
developmental stages and localization 24-25. Hematopoiesis in bone marrow (BM) 74 
is responsible for generation of major lineages of innate effectors, including NK 75 
cells, granulocytes, monocytes and dendritic cells.  While genetic switch in 76 
generation of innate immune system  has been identified 25, we are not aware of 77 
defects that predispose host to innate immune attack through increasing 78 
population sizes of self-destructive innate effectors. 79 
 80 
The mammalian target of rapamycin (mTOR) pathway, which couples energy 81 
and nutrient abundance to the execution of cell growth and division, has emerged 82 
as a major regulator of hematopoiesis.   Thus, activation of mTOR complex 1 83 
(mTORC1) by deleting Tsc1, which encodes a negative regulator for mTORC1 26, 84 
causes loss of hematopoietic stem cell (HSC) function and renders mice prone to 85 
leukemiogenesis in conjunction with loss of tumor suppressor Pten27-29. More 86 
recently, two groups reported that deletion of Rptor, which encodes a critical 87 
component of mTORC1 30-31, dramatically perturbed hematopoiesis in mice 32-33, 88 
as evidenced by defects in production of mature lymphoid and myeloid cells.  89 
Remarkably, cells with CD11b+ Gr-1- surface markers massively accumulated in 90 
BM following Rptor deletion in HSCs 32-33. The nature of this population and 91 
consequences of their accumulation, however, remains a mystery. 92 
 93 
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Here we systematically analyzed the gene expression signature, cell surface 94 
markers, morphology and functions of the CD11b+Gr-1- population in the Rptor-95 
deficient BM and other organs and sought for their physiological counterpart in 96 
the normal mice.  We found that these cells can be identified in both normal and 97 
Rptor-deficient hosts by CD3-B220-NK1.1-Ter119- CD11clow/-CD115-F4/80low/-Gr-98 
1- CD11b+PD-L1+ markers, lymphoid morphology and actively transcribed Ig loci.  99 
Interestingly, these cells broadly express essentially all TLRs along with many 100 
other pattern recognition receptors and mounted a greatly exacerbated response 101 
to all TLR ligands tested.  We name this population IMLEC for innate 102 
myelolymphoblastoid effector cell that can be derived from common myeloid 103 
progenitors.  Because their expansion and broad distribution render the host 104 
vulnerable to TLR ligands, we suggest that mTORC1-mediated repression of 105 
IMLEC expansion represents a new mechanism of immune tolerance in the 106 
innate immunity.  Our study also raises an intriguing perspective that while 107 
repressing mTOR over-activation suppresses leukemia, a functional mTORC1 108 
must be maintained to limit generation of IMLECs to avoid innate immune 109 
destruction. 110 
 111 
 112 
Results  113 
 114 
Raptor suppresses accumulation of a previously uncharacterized subset of 115 
leukocytes with features of both myeloid and lymphoid cells 116 
 117 
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As germline deletion of Rptor (which encode the Raptor protein) is embryonic-118 
lethal, we crossed mice harboring homozygous loxp-flanked Rptor exon 6 34 to 119 
those with interferon-inducible Mx1-Cre recombinase transgene, which allows 120 
inducible deletion of target genes effectively in the hematopoietic system upon 121 
treatment of interferon or its inducers 35. We treated the 6-8 weeks old Rptor F/F 122 
and Rptor F/F,Mx1-Cre mice with polyinosinic: polycytidylic acid (pIpC) every 123 
other day for 2 weeks to induce the deletion of Rptor. Hereafter, we refer to the 124 
pIpC-treated Rptor F/F mice as Ctrl (control) mice, while the Rptor F/F, Mx1-Cre 125 
mice as cKO (conditional knockout) mice (Figure 1A and Figure 1—figure 126 
supplement 1).  As has been reported by others 32-33, Rptor deletion causes 127 
broad defects in all lineages of hematopoietic cells (see also Figure 1—figure 128 
supplement 1, 2, 3).  However, the number of hematopoietic stem/progenitor 129 
cells (HSPCs) increased (Figure 1—figure supplement 4).  Most notably, 130 
CD11b+ Gr-1- cells, which amount to nearly 50% of BM cells in our model, 131 
emerge at the expense of CD11b+ Gr-1+ granulocytes from the cKO mice (Figure 132 
1B, C). Importantly, we also observed the massive accumulation of CD11b+Gr-1- 133 
cells in the BM of RptorF/F, Cre-ER mice after tamoxifen induced targeted 134 
mutation of Rptor, which clearly excludes the role of pIpC in  the generation of 135 
these cells (Figure 1—figure supplement 5). 136 
 137 
 The CD11b+ Gr-1- cells were smaller and had reduced granularity when 138 
compared to  CD11b+ Gr-1+ granulocytes, but were larger and more granular 139 
than the CD11b- Gr-1- cells (Figure 1—figure supplement 2E, F). Surprisingly, 140 
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despite the expression of myeloid marker CD11b on the expanded population of 141 
BM cells, histological analysis of BM section revealed pervasive expansion of 142 
lymphoblastoid cells (Figure 1D).  The cKO BM contained markedly decreased 143 
erythroid and myeloid lineage cells and markedly increased lymphocytes. 144 
Lymphocytes were predominantly small-to-medium sized and had normal 145 
cytological features. There was also an increased population of large blast-like 146 
cells with prominent nucleoli and perinuclear clearing resembling lymphoblasts. 147 
Plasma cells were present in small numbers. The myeloid: erythroid ratio was 148 
within normal range (3.04) but the overall number of erythroid and myeloid cells 149 
was very low. In particular, very few erythroid cells were present. In the myeloid 150 
lineage there was also maturation disruption since immature ring form 151 
neutrophils (neutrophilic metamyelocytes) predominate over mature neutrophils 152 
(condensed chromatin) (Figure 1D). Giemsa staining of BM smear revealed a 153 
massively increased lymphoblast population and severe depletion of both 154 
immature erythroid cells and granulocytes in the cKO mice (Figure 1E).  These 155 
cells were replaced by cells with prominent nucleoli and perinuclear clearing 156 
resembling lymphoblasts.  To confirm that the lymphoblasts were the CD11b+ Gr-157 
1- cells identified by flow cytometry in the cKO BM (Figure 1B, C), we FACS-158 
sorted the subset based on CD11b+ Gr-1- surface markers and validated its 159 
lymphoid morphology (Figure 1F).   160 
 161 
The spleen was greatly enlarged due to expansion of the follicular centers and 162 
periarteriolar sheaths within the splenic white pulp (lymphoid areas) of the cKO 163 
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mice (Figure 1—figure supplement 1C). The expanding white pulp populations 164 
consisted of lightly stained, large cells that morphologically resembled germinal 165 
center lymphocytes. In some areas, these populations expanded within the 166 
marginal zones while in others, they involved the periarteriolar sheaths. The cells 167 
had an increased amount of pale eosinophilic cytoplasm and mild pleomorphism 168 
with both centroblast-like cells (larger cells with large ovoid nuclei and 1-2 169 
prominent nucleoli per cell) and centrocyte-like cells (smaller cells with cleaved or 170 
elongated nuclei and unapparent nucleoli).. 171 
 172 
Since cells with such combination of morphology and surface markers had not 173 
been identified previously, we FACS-sorted the CD11b+ Gr-1- cells from the Rptor 174 
cKO BM and carried out next-generation RNA sequencing (RNA-seq).  Using 175 
principal component analysis (PCA), we compared gene expression profiles of 176 
these CD11b+ Gr-1- cKO BM cells with other known subsets of hematopoietic 177 
cells, including B cells, T cell subsets, NK cells, myeloid cell subsets, dendritic 178 
cells and erythroid cells.  This analysis demonstrates that the CD11b+Gr-1- cKO 179 
BM cells were distinct from all known blood cell types, although they appear to be 180 
closely related to B lymphocytes and macrophages (Figure 1G).  We hereafter 181 
refer these cells as innate myeloidlymphoblastoid effector cells (IMLECs). 182 
 183 
We identified subset specific genes using a threshold of 4-fold changes and an 184 
adjusted FDR-adjusted p-value <0.01. As shown in Figure 2A, by comparing 185 
RNA-seq data-based gene expression signature of all known leukocyte subsets, 186 
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a unique gene expression signature was identified in the CD11b+ Gr-1- cKO BM 187 
IMLECs. The signature consists of 48 genes that are up-regulated by more than 188 
4-fold. The 48 genes over expressed in the CD11b+ Gr-1- cKO BM IMLECs are 189 
listed in Figure 2B.  Among their diverse functions, these genes are involved in 190 
intracellular signaling cascades (such as Arhgap31, Rab20, Gna12, Mink1 and 191 
Prkch) and metabolic processes (such as Naga, Atf3, Aoah, Chst14 and Gns). 192 
The uniqueness of cKO BM IMLEC is also supported by pair-wise comparisons 193 
between IMLEC and peritoneal macrophage or other closely related cell types 194 
that are prominent in BM (Figure 2—figure supplement 1).  195 
 196 
A defining feature of the B cell lineage is activation of Ig gene loci, as evidenced 197 
by “sterile” transcripts transcribed from the unarranged loci of Ig heavy chain (Igh) 198 
and light chains (Igk and Igl) 36.  RNA-seq data revealed high levels of sterile 199 
transcripts within the Igh locus (Figure 2C) and Igk and Igl loci (Figure 2—figure 200 
supplement 2) from both B cell lineages and cKO BM IMLECs. This is a 201 
significant difference from macrophage, which had no detectable expression of 202 
the sterile transcripts, as expected.  Another defining feature of developing B-203 
lymphocytes is Ig gene rearrangement, a unique mechanism of genetic 204 
recombination that occurs only during the early stages of B cell maturation. This 205 
process is strictly dependent on recombinases genes Rag1 37-38 and Rag2 39-40.  206 
As shown in Figure 2D, no expression of Rag1 was detectable by quantitative 207 
PCR (qPCR), although a detectable but extremely low level of Rag2 was 208 
observed.  Consistent with lack of Rag1 expression, no gene rearrangement was 209 
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found in the Ig loci (Figure 2E).  Taken together, our data so far demonstrate that 210 
Raptor suppresses accumulation of a previously uncharacterized leukocyte 211 
subset with features of both myeloid and lymphoid cells.    212 
 213 
Characterization of IMLECs in Rptor cKO and WT mice 214 
IMLECs identified in the Rptor cKO mice did not express surface markers that 215 
are used to define other lymphocytes, such as B220 for B cells, CD3 for T cells 216 
and NK1.1 for NK cells (Figure 3A). The high levels of CD11b indicated that 217 
these cells are distinct from the recently identified innate lymphoid cells (ILCs) 218 
that are CD11b negative 41. In addition, they lack surface markers for progenitor 219 
cells, such as c-Kit and Sca-1 (Figure 3A). Although the cKO IMLECs retained a 220 
high level of myeloid marker CD11b, they expressed a very low level of F4/80 221 
macrophage marker and lacked CD115 monocyte marker (Figure 3B). To 222 
identify a positive marker for IMLEC, we searched our RNA-seq database for 223 
overexpression of genes that encode cell surface CD (cluster of differentiation) 224 
markers.  Among 317 CD markers (Supplementary file 1), the most up-225 
regulated gene in the cKO BM IMLECs over Ctrl whole BM cells was Cd274 (also 226 
called B7h1 or Pdl1).  As shown in Figure 3B and Figure 3C, PD-L1 was 227 
expressed on the vast majority of CD11b+ Gr-1- BM cells from Rptor cKO mice.   228 
 229 
Based on the above data and availability of robust cell surface markers, we 230 
define IMLECs by their expression of CD11b and PD-L1, but lack of major 231 
lineage markers for T cells (CD3), B cells (B220), natural killer cells (NK1.1), 232 
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erythroid cells (Ter119), granulocytes (Gr-1), macrophages and monocytes 233 
(F4/80 and CD115).  These markers allowed us to search wild-type BM for 234 
IMLEC. Interestingly, a clear although small fraction of the Lin- (CD3-B220- 235 
NK1.1- Ter119- Gr-1- F4/80- CD115-) CD11b+ BM cells in the Ctrl mice also 236 
expressed PD-L1 (Figure 3C, left panel), although the overall PD-L1 expression 237 
level was not as high as that from cKO IMLECs.  Following Rptor deletion, a 238 
robust expansion (approximately 500-fold) of Lin- CD11b+ PD-L1+ BM IMLECs 239 
was observed (Figure 3C, right panel). 240 
 241 
It should be noted that although cKO IMLECs also over-express Cd11c gene 242 
(Supplementary file 1), IMLEC gene expression profiles are distinct from 243 
dendritic cell (DC) based on gene signature (Figure 1G and Figure 2—figure 244 
supplement 1E, F). In cKO IMLECs, the CD11c levels were somewhat lower 245 
than the PD-L1- DC (Figure 3D).  In WT mice, greater than 90% of Lin-246 
CD11b+PD-L1+ IMLEC in BM, lung and peripheral blood mononuclear cells 247 
expressed only low levels of CD11c, while  those in spleen  and mesenteric 248 
lymph nodes consisted of two major subsets: CD11chigh and CD11clow/- (Figure 249 
3E). IMLECs were also found among the leukocytes isolated from lung and in 250 
peripheral lymphoid organ (Figure 3F, 3G, 3H), and this population was greatly 251 
expanded in the cKO mice (Figure 3I).   252 
 253 
To further confirm that this subset is the IMLEC in normal BM, we FACS-sorted 254 
the Lin- (CD3- B220- NK1.1- Ter119- Gr-1- F4/80- CD115-) CD11b+ PD-L1+ cells 255 
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from wild type (WT) BM and characterized their morphology and levels of sterile 256 
Ig transcripts.  As shown in Figure 4A, the sorted cells had a lymphoid 257 
morphology as did the cKO IMLECs. They also displayed comparable size and 258 
granularity as cKO IMLECs (Figure 4B).  Moreover, Lin- CD11b+ PD-L1+ cells 259 
from WT BM expressed sterile transcripts of Ig loci identified by RNA-seq (Figure 260 
4C). Furthermore, subsequent validation of IMLECs in WT BM was undertaken 261 
by comparing the expression of other top candidate markers (CD14, CD16) and 262 
MHC-I/MHC-II (Figure 4—figure supplement 1A), as well as population-specific 263 
transcription factors Mitf, Atf3 and Zdhhc1 (Figure 4 D, E). The largely 264 
comparable expression levels of these surface markers and transcription factors 265 
between WT and cKO IMLECs provide additional lines of evidence for these cells 266 
to be naturally occurring IMLECs. Therefore, a small fraction of normal 267 
leukocytes in lymphoid and non-lymphoid tissues have the IMLEC phenotype, 268 
and this subset is massively expanded after Rptor deletion.  269 
  270 
 271 
Altered differentiation is responsible for accumulation of IMLECs 272 
Theoretically, expansion of IMLECs in cKO BM may be caused by increased 273 
proliferation and/or reduced apoptosis.  To test this possibility, we analyzed the 274 
proliferation of IMLECs by Ki-67 staining and BrdU incorporation.  Remarkably, 275 
Lin- CD11b+ PD-L1+ IMLECs from both Raptor Ctrl and cKO BM had much fewer 276 
Ki-67+ cells (Figure 4F,G) or BrdU+ cells (Figure 4—figure supplement 1B, C) 277 
when compared with other lineages.  The fact that IMLECs are not proliferating at 278 
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a higher rate than other BM cell types effectively rules out rapid proliferation as 279 
an explanation for IMLECs accumulation in Raptor cKO BM. Likewise, the 280 
massive increase of IMLEC in cKO mice over those in the Ctrl mice cannot be 281 
due to proliferation, as the percentage of Ki-67+ or BrdU+ cells is not increased in 282 
cKO mice. Furthermore, based on cell surface Annexin V staining, IMLECs from 283 
cKO BM were more prone to apoptosis than total lineage+ population (Figure 4H, 284 
I) and had apoptosis rate that was comparable to granulocytes, B cells and T 285 
cells in BM (Figure 4—figure supplement 1D, E).  The pronounced apoptosis 286 
also rules out the possibility that increased survival may account for preferential 287 
accumulation of IMLECs in cKO mice. The robust apoptosis detected among WT 288 
IMLECs likely contributed to the reduced amount of IMLECs in normal BM 289 
(Figure 3C).  Consistent with the reduced proliferation and increased apoptosis 290 
of IMLECs, our exhaustive efforts to demonstrate self-renewal of IMLEC through 291 
transplantation of massive numbers of IMLEC have all been unsuccessful (data 292 
not shown).  293 
 294 
As an alternative hypothesis, we evaluated whether IMLECs accumulated 295 
because of altered differentiation of hematopoietic stem and progenitors 296 
(HSPCs).  As the first step to test this hypothesis, we evaluated if IMLEC 297 
accumulation in cKO BM was cell-intrinsic.  Briefly, we mixed either RptorF/F or 298 
RptorF/F, Mx1-Cre (both CD45.2+) BM cells with recipient type CD45.1+ WT BM 299 
cells at a 2:1 ratio.  At six weeks after BM transplantation, Rptor was deleted 300 
from the RptorF/F, Mx1-Cre donor-derived cells by pIpC treatment (Figure 5A).  301 
 14 
As shown in Figure 5B, the accumulation of CD11b+ Gr-1- IMLECs was intrinsic 302 
to Rptor -/- BM cells. Since our earlier data suggested that IMLECs accumulated 303 
at the expense of granulocytes (Figure 1B, C), we tested if granulocytes were 304 
converted to IMLECs following Rptor deletion.  We produced RptorF/F, Lyz2-305 
Cre+/+ mice that should have myeloid lineage-specific deletion of Rptor.  However, 306 
despite the effective deletion of the Rptor gene in the granulocytes (Figure 5C), 307 
the percentages of CD11b+ Gr-1+ granulocytes and CD11b+ Gr-1- IMLECs were 308 
unchanged (Figure 5D). These data suggest that accumulation of IMLEC in the 309 
cKO mice was not due to trans-differentiation from granulocytes. 310 
 311 
Next, we use both in vitro co-culture and in vivo BM transplantation to identify the 312 
progenitor that may give rise to IMLECs. We co-cultured OP9 stromal cells with 313 
FACS-sorted BM LSK (Lin- Sca-1+ c-Kit+), CMP (Lin- Sca-1- c-Kit+ CD34Medium 314 
CD16/32Medium) and CLP (Lin-CD127+ Sca-1Mediumc-KitMedium) populations from Ctrl 315 
and cKO mice that had been treated with pIpC (Figure 5E). As shown in Figure 316 
5F, both LSK and CMP populations from Rptor-/- BM gave rise to CD11b+ Gr-1- 317 
PD-L1+ IMLECs. As expected, Rptor-sufficient CLPs were not able to give rise to 318 
CD11b+ myeloid cells. Interestingly, Rptor-deficient CLPs generated progenies 319 
with a small portion exhibiting immunophenotypes of IMLECs. We also 320 
transplanted sorted LSK and CMP populations and induced Rptor deletion in the 321 
donor cells by treating recipients with pIpC (Figure 5G) to confirm their ability in 322 
giving rise to IMLECs.  Due to lack of self-renewal activity of progenitor cells and 323 
rapid apoptosis of IMLEC, we used a much shorter timeline than the whole bone 324 
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marrow transplantation studies in order to capture progenitor-derived IMLEC.  As 325 
shown in Figure 5H, deletion of Rptor in either LSKs or CMPs was sufficient to 326 
induce the generation of CD11b+ Gr-1-PD-L1+ cells in recipients BM.  The shorter 327 
timeline explained relative paucity of LSK-derived IMLEC when compared with 328 
long-term bone marrow transplantation (Figure 5A, B).  As expected, since 329 
CMPs do not have self-renewal capability, only a small number of progeny cells 330 
were produced.  However, since IMLEC can be generated from CLP in vitro, their 331 
potential to do so under physiological conditions cannot be ruled out. Taken 332 
together, our data demonstrate that the massive accumulation of IMLECs in cKO 333 
mice can be caused by altered differentiation of CMPs, although other 334 
differentiation pathway cannot be ruled out. 335 
 336 
Reduced c-Myb expression is responsible for accumulation of IMLECs 337 
A previous study demonstrated that heterozygous Myb mutation leads to an 338 
expansion of BM CD11b+Gr-1- cells 42.  Although expression of PD-L1 was not 339 
evaluated in the earlier study, we were intrigued by the possibility that down-340 
regulation of Myb may be the underlying mechanism for the massive production 341 
of IMLECs.  Since both LSKs and CMPs are able to give rise to CD11b+ Gr-1- 342 
PD-L1+ IMLECs, we evaluated expression of c-Myb in both LSK and CMP 343 
populations. Indeed, the Myb transcripts were significantly reduced in both LSK 344 
and CMP populations sorted from Rptor cKO mice (Figure 6A).  Moreover, our 345 
intracellular staining also revealed reduced levels of c-Myb protein in both LSKs 346 
and CMPs from cKO BM (Figure 6B). Interestingly, induced deletion of c-Myb in 347 
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mice with homozygous floxed c-Myb (MybF/F, Mx1-Cre), but not heterozygous 348 
floxed c-Myb (MybF/+, Mx1-Cre), showed obvious increase of PD-L1 expression 349 
in CD11b+Gr-1- BM cells (Figure 6C, D, E and Figure 6—figure supplement 1A, 350 
B, C), despite of significant decrease of BM whole leukocytes due to Myb-351 
reduction induced cell apoptosis. To avoid excessive apoptosis and test if the 352 
down-regulation of Myb was necessary and sufficient to cause accumulation of 353 
IMLECs, we transplanted BM cells from either MybF/F, Rag2-/- or MybF/F, Rag2-/- , 354 
CreER mice to CD45.1+ recipients, which then received tamoxifen to achieve 355 
deletion of Myb specifically in donor-derived hematopoietic cells after their full 356 
reconstitution (Figure 6F). Consistent with essential role for c-Myb in 357 
hematopoiesis, surviving leukocytes appeared heterozygous for Myb deletion 358 
(Figure 6G).  As early as 1 week after the first injection of tamoxifen, a significant 359 
decrease in CD11b+ Gr-1+ granulocytes and an increase in CD11b+ Gr-1- PD-L1+ 360 
IMLECs were observed in Myb cKO BM (Figure 6H). Moreover, the provision of 361 
heterologous c-Myb significantly diminished the generation of IMLECs from 362 
Raptor-deficient LSK cells in our in vitro OP9 co-culturing experiments (Figure 363 
6—figure supplement 1D, E, F, G). Therefore, down-regulation of Myb is 364 
necessary for production of IMLECs. 365 
 366 
We recently reported that deletion of Rptor caused up-regulation of miRNA 367 
biogenesis in HSPCs 43.  We searched our miRNA microarray database and 368 
mirSVR score database44  for potential impact of miRNAs in down-regulation of 369 
Myb expression.  Using the stringent criteria of mirSVR score <-1.0, we identified 370 
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50 miRNAs that presented in the HSPCs (Supplementary file 2).  Among them, 371 
13 miRNAs showed >2.0 folds up-regulation in the Rptor-deficient HSPCs 372 
(P<0.05), while none showed statistically significant down-regulation (Figure 6I).  373 
Significant up-regulation of miR-150 (1.4 folds increase, P=0.05), which was 374 
previously demonstrated to inhibit Myb expression 45-46, was also observed.  Up-375 
regulation of Myb-targeting miRNAs provides a plausible mechanism for down-376 
regulation of Myb by Rptor deletion.  However, the broad spectrum of the up-377 
regulated miRNAs suggests that it is unlikely that a single miRNA is responsible 378 
for the overall reduction of Myb expression.   379 
 380 
Expansion of IMLECs associated with lethal inflammatory response to TLR 381 
ligands 382 
RNA-seq data indicated that IMLECs broadly up-regulate pattern recognition 383 
receptors (PRRs) genes. TLRs, the first family of PRRs identified, were broadly 384 
over-expressed in cKO IMLECs as determined by RNA-seq (Figure 7A). RT-385 
PCR confirmed that IMLECs from both cKO and WT mice over-expressed 386 
essentially all TLRs tested, particularly Tlr2, Tlr3, Tlr4, Tlr6, Tlr7, Tlr8 and Tlr9 387 
(Figure 7B). In addition to TLRs, expression of other PRRs, including NLRs, 388 
ALRs and RLRs, was also broadly elevated (Figure 7—figure supplement 1).  389 
When the BM from Ctrl and Rptor-/- mice were compared for their responses to 390 
TLRs agonists, including synthetic tripalmitoylated lipopeptide Pam3CysSerLys4 391 
(Pam3CSK4, TLR1/2 agonist), heat-killed Listeria monocytogenes (HKLM, TLR2 392 
agonist), synthetic analog of double-stranded RNA poly I:C (pIpC, TLR3 agonist), 393 
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lipopolysaccharide (LPS, TLR4 agonist), flagellin from Salmonella typhimurium 394 
(FLA-ST, TLR5 agonist), synthetic lipoprotein derived from Mycoplasma 395 
salivarium (FSL-1, TLR2/6 agonist), single-stranded RNA Double-Right 396 
complexed with LyoVec™ (ssRNA-DR, TLR7 agonist) and synthetic 397 
oligonucleotides containing unmethylated CpG dinucleotides (ODN1826, TLR9 398 
agonist), it is clear that Rptor-/-  BM increased production of TNF-α (Figure 7C) 399 
and MCP-1(Figure 7D) in response to all TLR ligands tested. To determine the 400 
cellular basis for the enhanced cytokine production, we used intracellular and cell 401 
surface staining to identify cells that produced the inflammatory cytokines.  As 402 
shown in Figure 7E, IMLECs from both WT and Rptor cKO BM were potent 403 
producers of TNF-α when stimulated by LPS.  404 
 405 
Consistent with exacerbated responses to TLR ligands in BM cells, deletion of 406 
Rptor in cKO mice resulted in massive increase in inflammatory cytokines in 407 
serum (Figure 8A).  Approximately 40% of cKO mice died within 2 months after 408 
7 pIpC treatments (Figure 8B). Histological analyses revealed extensive 409 
inflammation in the liver with associated tissue injuries (Figure 8C). A substantial 410 
proportion of the leukocytes in the liver of cKO mice were IMLECs, as 411 
demonstrated by cell surface markers CD11b+ Gr-1- PD-L1+ F4/80low/- (Figure 8D, 412 
E).  To test if the mice with expanded IMLECs were more sensitive to endotoxin, 413 
we challenged the Ctrl and cKO mice with low doses of LPS (5mg/kg body 414 
weight). While all Ctrl mice survived the LPS challenge, all cKO mice succumbed 415 
within 36 hours (Figure 8F). The dramatically increased mortality due to 416 
 19 
endotoxic shock was associated with remarkably elevated levels inflammatory 417 
cytokines.  As shown in Figure 8G and Figure 8H, a more than 500-fold 418 
increase in TNF- and an approximately 10-fold increase of MCP-1 were 419 
detected in the serum of cKO mice at 6 hours after LPS injection. It has been 420 
demonstrated that acetaminophen-triggered liver necrosis induces HMGB-1-421 
mediated inflammatory responses to danger-associated molecular patterns 422 
(DAMPs)11, 47. As shown in Figure 8I and Figure 8J, cKO mice mounted a 423 
significantly elevated inflammation to challenge by low doses of acetaminophen. 424 
Therefore, amplification of IMLEC also leads to elevated response to tissue 425 
injuries. 426 
 427 
Since Mx1-Cre was broadly activated after pIpC treatment, it is less certain 428 
whether the increased sensitivity of the cKO mice to TLR ligands is due to 429 
immunological abnormality.  To address this issue, we produced chimeric mice in 430 
which pIpC induces deletion of the targeted gene exclusively in hematopoietic 431 
cells by transplanting RptorF/F, Mx1-Cre (CD45.2+) BM cells into lethally irradiated 432 
CD45.1+ recipients.  After hematopoietic reconstitution, the recipients were 433 
treated with 3 doses of pIpC to induce deletion of Rptor exclusively in the 434 
hematopoietic cells. After 10 days of pause, the Ctrl and cKO chimera mice were 435 
challenged with new pIpC injection and monitored for survival (Figure 9A).  As 436 
shown in Figure 9B, while a large portion of the cKO chimera mice died 437 
progressively starting within a week of the second round of pIpC treatment, all 438 
Ctrl chimera mice survived the observation period of more than 45 days.  439 
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Massive leukocytes infiltration was observed in the liver of cKO chimeric mice 440 
(Figure 9C). Cell surface phenotyping of the donor-type leukocytes in BM 441 
(Figure 9D), spleen (Figure 9E) and liver (Figure 9F) revealed accumulation of 442 
CD11b+ Gr-1- PD-L1+ F4/80low/- IMLECs.  Collectively, the data in Figure 8 and 443 
Figure 9 demonstrate that over-expansion of IMLECs, as a result of Rptor 444 
deletion, renders the host highly vulnerable to TLR ligands. 445 
 446 
 447 
Discussion 448 
 449 
We have characterized a leukocyte population, which we called IMLECs, that has 450 
a strong innate effector function but with features of both myeloid and lymphoid 451 
cells. Furthermore, our data reveal an unexpected function of mTORC1 in 452 
suppressing IMLEC expansion.  The high vulnerability to TLR ligands after 453 
IMLEC expansion highlights a new consequence of defective hematopoiesis and 454 
a new mechanism of immune tolerance.  455 
 456 
Two groups have previous reported that inactivation of mTORC1 by deletion of 457 
Rptor leads to massive accumulation of CD11b+Gr-1- cells in the BM 32-33.  458 
Similar results were obtained in mice with Mtor deletion in the hematopoietic cells 459 
48.  We have demonstrated here that despite expression of a myeloid cell marker 460 
CD11b, the CD11b+Gr-1- BM cells have lymphoid morphology.  The active 461 
production of sterile transcripts at Ig loci suggests that these cells have partially 462 
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committed to the B-cell lineage, while lack of VDJ rearrangement and cell surface 463 
B cell markers suggest that the differentiation toward the B cell lineage is limited. 464 
Importantly, this cell population expresses high levels of PD-L1 but does not 465 
express markers for other lymphoid cells including T cells (CD3) and NK cells 466 
(NK1.1) as well as for myeloid cells including F4/80, Gr-1 and CD115.  467 
Expression of CD11b also distinguishes IMLECs from ILCs 41, which are CD11b-.  468 
PCA analysis demonstrated that IMLECs are distinct from but close to B cells 469 
and macrophages in gene expression profiles.  While at much lower frequencies, 470 
cells with the same phenotypes and functional properties were also identified in 471 
normal BM, peripheral lymphoid and non-lymphoid organs.  472 
 473 
It is of interest to note that the hallmark of IMLECs is the high expression of cell 474 
surface PD-L1. First identified as B7-H1 49, PD-L1 has been shown to be 475 
involved in tumor evasion of T cell immunity, both by inducing exhaustion of 476 
effector T cells and by shielding tumor cells from effector T cells 50-51.  With the 477 
induction by cytokines such as IFN- and hypoxic tumor microenvironment, PD-478 
L1 has been found on both tumor cells and host inflammatory cells such as 479 
myeloid derived DCs 52-53, tumor-infiltrating myeloid derived suppressor cells 54. 480 
Recent studies have demonstrated that PD-L1 is an important biomarker and 481 
therapeutic target in cancer immunotherapy 55-56.  Since IMLECs constitutively 482 
express high levels of PD-L1, it will be of interest to investigate their function in 483 
cancer immunity. It’s worth noting that IMLECs of Raptor-deficient BM have an 484 
overall higher expression of PD-L1 than that of Raptor-sufficient BM, perhaps this 485 
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reflects the indirect consequence of reduced mTORC1-mediated translation of 486 
PD-L1 negative regulators. 487 
 488 
Since the IMLEC population expanded at the expense of granulocytes in the BM, 489 
we tested if IMLECs were derived by trans-differentiation of the granulocytes. 490 
Our genetic analyses demonstrated that inactivation of mTORC1 in the 491 
granulocytes, using Lyz2-Cre, failed to produce this subset, suggesting that loss 492 
of mTORC1 in granulocytes does not cause their trans-differentiation into 493 
IMLECs. Furthermore, since inactivation of mTORC1 in CD11b+Gr-1+ 494 
granulocytes did not affect their abundance in BM, loss of granulocytes in the 495 
mice with broad deletion of Rptor in all hematopoietic cells was not due to a cell-496 
intrinsic requirement for mTORC1 in survival of granulocytes. Since IMLECs 497 
generally do not undergo active proliferation and are prone to apoptosis, their 498 
massive accumulation is most likely due to continuous production rather than 499 
self-renewal.  Indeed, while LSKs and CMPs differentiate into IMLECs both in 500 
vitro and in vivo, IMLECs are not able to propagate in vivo (data not shown).  501 
Since Lyz2-Cre mediated Rptor deletion does not result in accumulation of 502 
IMLECs, it is obvious that IMLEC differentiation pathway is initiated before Lyz2-503 
Cre expression which also occurs in some CMPs, and not all CMPs can give rise 504 
to IMLEC.  On the other hand, since CLPs give rise to IMLEC in vitro, the 505 
possibility that other progenitor cells may give rise to IMLECs has not been ruled 506 
out.  507 
 508 
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Since heterozygous mutation of Myb causes an increase of CD11b+Gr-1low/- cells 509 
in BM 42, we tested if conditional deletion of Myb is sufficient to cause 510 
accumulation of IMLEC.  Our data demonstrate that cell-intrinsic reduction of 511 
Myb in BM resulted in accumulation of CD11b+ Gr-1- PD-L1+ IMLECs.  It is of 512 
interest to note that mice with inactivation of Rptor share many hematopoietic 513 
phenotypes with mice harboring targeted disruption of Myb, such as an increase 514 
in HSPCs 57 and defective B-lymphopoiesis58-60.  Moreover, consistent with the 515 
proposed roles of c-Myb in regulating precise hematopoietic commitments, CMPs 516 
with deletion of either Rptor or Myb favored differentiation to CD11b+ Gr-1- cells 61. 517 
Since our data show that the majority of the CD11b+Gr-1- cells generated from 518 
CMPs are IMLECs, these data support the notion that IMLEC accumulation in 519 
Rptor cKO BM is caused by reduced Myb expression in CMPs.  520 
While the mechanism by which mTORC1 down-regulates Myb remains to be fully 521 
elucidated, we have found a general up-regulation of putative miRNAs targeting 522 
Myb in HSPCs after Rptor deletion. Our data suggest that mTORC1 inactivation 523 
in HSPCs expands IMLECs by down-regulation of Myb, perhaps through 524 
increased miRNA biogenesis. 525 
 526 
Previous studies by us and others have demonstrated a critical role for regulated 527 
mTOR signaling in hematopoiesis 27-28, 62. Thus, while mTOR activation by 528 
deletion of Tsc1 complex expands the numbers of hematopoietic stem cells, it 529 
causes reduced hematopoietic stem cell function but induced leukemic stem cells 530 
in conjunction with Pten deletion.  This is consistent with the generally accepted 531 
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association between defective differentiation and leukemiogenesis, which forms 532 
the foundation for treatment of leukemia through induction of differentiation 63.  533 
The expansion of IMLECs caused by mTORC1 inactivation did not lead to 534 
leukemiogenesis as IMLECs are non-dividing cells that undergo a high rate of 535 
apoptosis. Instead, our data demonstrate a new consequence of defective 536 
differentiation, namely generation of a new population of cells with distinct 537 
effector function, as discussed below. 538 
 539 
Our RNA-seq data suggest that IMLECs broadly over-express pattern recognition 540 
receptors for innate immunity.  Corresponding to a broad, although not universal 541 
TLR elevation, IMLECs mount drastically exacerbated responses to all TLR 542 
ligands tested in vitro. Intracellular cytokine staining revealed that both normal 543 
and Rptor-cKO IMLECs were among the most active producers of inflammatory 544 
cytokines. Surprisingly, although Rptor-/- BM cells have normal TLR5 levels, they 545 
produce 10-20 fold more inflammatory cytokines, such as TNF- and MCP-1 in 546 
response to TLR5 ligand.  It is therefore likely that beyond TLRs, IMLECs have 547 
acquired other features that enhance their response to TLR ligands.  548 
 549 
 Apart from BM, expanded IMLECs are broadly distributed in lymphoid and non-550 
lymphoid organs such as lung and liver.  Our data demonstrate that an increase 551 
in IMLEC numbers makes the host highly vulnerable to TLR ligands such as LPS 552 
and polyI:C, as indicated by rapid demise of mice following pIpC and low doses 553 
of LPS injections.  Since necrosis of normal tissues leads to release of 554 
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endogenous TLR ligands, such as HMGB147 and HSP70 64, and since 555 
unregulated host response to HMGB1 leads to fatal inflammation11, it is 556 
conceivable that expansion of IMLECs may also make the host more vulnerable 557 
to tissue injury- induced inflammation. This is evidenced by elevated 558 
inflammation in acetaminophen-triggered liver necrosis model. 559 
 560 
The severe pathological consequences may explain the paradoxical functions of 561 
mTOR in regulation of inflammation.  While mTOR signaling is known to be 562 
activated by inflammatory cytokines 65 and rapamycin has been shown to inhibit 563 
production of inflammatory cytokines 66, perhaps through its inhibition of mTOR-564 
mediated NFB activation 67, rapamycin has been shown to induce inflammation 565 
in a small number of transplantation patients 68-70.  Likewise, we have observed 566 
that rapamycin increases production of inflammatory cytokines in autoimmune 567 
Scurfy mice and in mice treated with high doses of endotoxin 65.  It would be of 568 
great interest to determine if rapamycin can expand IMLECs in transplantation 569 
patients and in mice that either receive high doses of endotoxin or are genetically 570 
predisposed to autoimmune disease. It is also reported that persistent mTORC1 571 
inhibition can result in elevated inflammation, activation of STAT3 and enhanced 572 
hepatocellular carcinoma development 71. Our findings focused on characterizing 573 
IMLECs and inflammation support the provocative findings of this report, and 574 
might provide alternative and complementary explanations. However, despite an 575 
extensive effort, we have failed to induce IMLECs by mTOR kinase inhibitor 576 
Torin2 or rapamycin in WT mice (data not shown). Therefore, under normal 577 
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circumstances, pharmaceutical inhibition of mTORC1 alone cannot achieve 578 
comparable levels of inflammation as those achieved by genetic inactivation of 579 
either Mtor or Rptor.  Additional conditions must be met for mTOR inhibitors to 580 
cause inflammation.  While these unknown barriers have ensured safety of 581 
mTOR inhibitors in most circumstances, their breakdown may explain 582 
paradoxical induction of inflammation by rapamycin.  583 
 584 
The concept of immune tolerance has traditionally been reserved for adaptive 585 
immunity to avoid autoimmune diseases.  A multitude of mechanisms, including 586 
clonal deletion 22-23, 72, clonal anergy 2, 73 and dominant regulatory T cells 3, have 587 
been described to reduce self-reactive T and B cell clone sizes to avoid 588 
autoimmune diseases. On the other hand, innate immunity is known to be 589 
regulated at levels of cellular activation 74 and cellular recruitment 75.  However, 590 
we and others have reported that innate immune effectors, especially NK cells, 591 
have features of adaptive immunity as their immune protective function against 592 
cancer and viruses is amplified through increased population sizes 76-77.  593 
However, a regulatory mechanism to control innate effector population size for 594 
the sake of preventing self-destruction has not been described. Our discovery of 595 
a developmentally regulated mechanism to control the population size of IMLECs 596 
to avoid unwanted self-destruction, as described herein, reveals a parallel 597 
between adaptive and innate immunity to avoid potentially life-threatening 598 
inflammation and tissue damage.  It is therefore of interest to consider the 599 
concept of immune tolerance in the area of innate immunity.   600 
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 601 
An important consideration is whether IMLEC is a normal population of 602 
hematopoietic cells or a population that arises after pathogenic mutations.  While 603 
we have identified cells of similar phenotypes and functional properties in normal 604 
mice, they are extremely rare and thus have no obvious physiological functions 605 
unless they are substantially expanded.  We have demonstrated that these cells 606 
do not undergo proliferation and are prone to apoptosis, and that their expansion 607 
depends on abnormal hematopoiesis.  Therefore, the pathological consequence 608 
observed herein is only known to manifest itself if the mTORC1-MyB pathway is 609 
genetically inactivated, resulting in disruption of normal hematopoiesis.  Further 610 
studies are needed to identify conditions that can lead to accumulation of IMLEC 611 
short of these known mutations. 612 
 613 
In summary, our data demonstrate that inactivation of mTORC1 in hematopoietic 614 
stem/progenitor cells leads to generation of IMLECs, a new cell population that 615 
shares features with myeloid and lymphoid lineages. The greater than 500-fold 616 
increase in population size of IMLECs in mTORC1- or MyB-defective BM 617 
highlights the critical role for mTORC1  and MyB in repressing the development 618 
of sufficient number of IMLECs to cause serious inflammation and tissue damage. 619 
Our study reveals a new consequence of defective hematopoiesis and may help 620 
to extend the concept of immune tolerance to innate immunity. 621 
 622 
Materials and Methods 623 
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Key Resources Table 624 
Reagent type (species) or 
resource 
Designation Source or 
reference 
Identifiers Additional 
information 
strain, strain background (Mus 
musculus,C57BL/6) 
RptorF/F PMID: 19046572    
strain, strain background (Mus 
musculus,C57BL/6) 
MybF/F;  
MybF/F,Rag2-/-
,CreER 
PMID: 
15195090; 
PMID: 16169500 
   
strain, strain background (Mus 
musculus,C57BL/6) 
Mx1-Cre The Jackson 
Laboratory 
Stock No: 003556; 
RRID:IMSR_JAX:003556 
 
strain, strain background (Mus 
musculus,C57BL/6) 
CreER The Jackson 
Laboratory 
Stock No: 007001; 
RRID:IMSR_JAX:007001 
 
strain, strain background (Mus 
musculus,C57BL/6) 
Lyz2-Cre The Jackson 
Laboratory 
Stock No: 004781; 
RRID:IMSR_JAX:004781 
 
 625 
 626 
Mice and induction of gene deletion  627 
Rptor F/F mice 78 were crossed to the C57BL/6 background for more than 10 628 
generations. Myb F/F and Myb F/F, Rag2-/- , CreER mice were reported 629 
previously58-59, 79. The interferon-inducible Mx1-Cre transgenic mice 630 
(RRID:IMSR_JAX:003556) 35, tamoxifen-inducible Cre-ERT2 transgenic mice 631 
(RRID:IMSR_JAX:007001) 80 and Lyz2-Cre knock-in mice 632 
(RRID:IMSR_JAX:004781) 81 with C57BL/6 background were purchased from the 633 
Jackson Laboratory. Rptor F/F mice were crossed with Mx1-Cre mice, Lyz2-Cre 634 
mice or CreER mice to produce Rptor F/F, Mx1-Cre (cKO) mice, Rptor F/F, Lyz2-635 
Cre+/+ mice or RptorF/F, CreER mice, respectively. Myb F/F mice were crossed 636 
with Mx1-Cre mice to generate MybF/F (Ctrl) and MybF/F, Mx1-Cre (cKO) mice. 637 
Offspring of these mice were genotyped by PCR-based assays with genomic 638 
DNA from mouse tail snips.  Mice were cared for in the Unit of Laboratory Animal 639 
Medicine (ULAM) at the University of Michigan, where these studies were 640 
initiated, or Research Animal Facility (RAF) of Children’s National Medical Center, 641 
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where the studies were completed. All procedures involving experimental 642 
animals were approved by the University Committee on the Use and Care of 643 
Animals (UCUCA) at the University of Michigan or Children’s National Medical 644 
Center. 645 
 646 
Raptor Ctrl and cKO mice used in each experiment were sex-matched littermates. 647 
Mice were given 2 mg/kg body weight of pIpC (GE Healthcare Life Sciences) or 648 
400µg pIpC (Sigma-Aldrich) every other day for consecutive 3 to 7 times as 649 
specified by intra-peritoneal (i.p.) injection to induce Cre expression as in 650 
previous study 82. Deletion of target genes were confirmed as previously 651 
described78-79. Wild type C57BL/6 (CD45.2) mice and congenic C57BL/6 (CD45.1) 652 
mice were purchased from the Charles River Laboratories.  Tamoxifen (Sigma-653 
Aldrich) was dissolved in corn oil (Sigma-Aldrich) to 20 mg/ml and injected i.p. at 654 
150 mg/kg/day for 5 consecutive days.  655 
 656 
Histology, cytology and complete blood cell count 657 
Ctrl and cKO mice were euthanized by CO2 inhalation on day 30 of last pIpC 658 
treatment. For histology, tissues were fixed in 10% neutral buffered formalin for 659 
24-48 hours and the sternums were then decalcified in Immunocal (formic acid-660 
based decalcifier, Decal, Tallman, NY) for 24 hours. Tissues were trimmed and 661 
cassetted and processed to wax on an automated processor using standard 662 
methods. Sections were cut at 5 m thickness and hematoxylin and eosin-663 
stained slides prepared on an automated stainer. For cytology, BM was collected 664 
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from the femoral marrow cavity with a fine diameter paintbrush dipped in sterile 665 
PBS with 5% fetal bovine serum and cytology smears were prepared by gently 666 
brushing the collected cells in parallel lines on a glass slide. Cytology slides of 667 
BM smear and cytospins of FACS-sorted BM cells were stained using a 668 
Romanowsky-based stain (Diff-Quik, Hema 3 Manual staining system, Fisher 669 
Scientific).   670 
 671 
Histological and cytological parameters were evaluated using an Olympus BX45 672 
light microscope at total magnifications ranging from 40 X to 100 X (oil). 673 
Histological alterations were descriptively identified. Cytological alterations were 674 
descriptively identified and quantitative BM differential counts were made using a 675 
manual differential counter and standard criteria for cell identification. Images 676 
were taken using a 12.5 megapixel microscope-mounted Olympus DP72 digital 677 
camera and accompanying software (Olympus). Complete blood cell count was 678 
performed using the Hemavet 950 Hematology System (Drew Scientific Inc.) by 679 
the Animal Diagnostic Laboratory of ULAM Pathology Cores for Animal Research 680 
in the University of Michigan.  681 
 682 
Cells preparation and bleeding 683 
BM cells were flushed out from the long bones (tibiae and femurs) by a 25-gauge 684 
needle with staining buffer (1XHanks Balanced Saline Solution without calcium or 685 
magnesium, supplemented with 2% heat-inactivated fetal bovine serum). Single 686 
cell suspensions of spleen, thymus, lung and lymph nodes were generated by 687 
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gently squashing with frosted slides in a small volume of staining buffer. Cells 688 
from mouse peritoneal cavity were harvested as described before83. For isolation 689 
of mouse liver mononuclear cells, liver fragments were pressed through 70μm 690 
round cell strainer (Becton Dickinson). Single-cell suspensions in a 35% Percoll 691 
solution (GE Healthcare) were centrifuged for 20 minutes at 800g with brake off 692 
at room temperature. Pellet was collected and washed with staining buffer. 693 
Peripheral blood was collected by retro-orbital bleeding with heparinized capillary 694 
tubes or by submandibular bleeding with a lancet.  695 
 696 
Flow cytometry 697 
For surface staining, cells were stained with the indicated antibodies (Abs) in 698 
staining buffer for 20 minutes at 4 °C. In the characterization of surface markers 699 
for CD11b+ Gr-1- cells, Fcγ receptors were pre-blocked by incubating cells with 700 
culture medium from  hybridoma 2.4G2 84 for 20 minutes at 4°C. For intracellular 701 
staining, cells were first stained with the indicated surface markers Abs and then 702 
fixed with Cytofix/Cytoperm buffer (BD Biosciences) for 1-2 hours at 4°C, 703 
followed by incubation with Cytoperm Plus buffer (BD Biosciences) for 15 704 
minutes at room temperature (R.T.). After refixing for 15 minutes at R.T., cells 705 
were incubated with antibodies or isotype controls for 20 minutes (anti-TNF/IgG, 706 
anti-Ki-67Abs) or overnight (anti-c-Myb/IgG Abs) and further stained with the 707 
secondary Ab if necessary. BrdU labeling experiments were performed per the 708 
manufacture’s instruction (BD Biosciences), as previously reported 29, 82. 709 
Apoptosis assays by 7-AAD and Annexin V (BD Biosciences) were according to 710 
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manufacturer’s instructions. All FACS analyses were performed on a BD LSR II 711 
or a Canto II Flow Cytometer, and data were analyzed with FlowJo software 712 
(Tree Star, Inc.). The enrichment of Lin- BM cells was performed using MACS 713 
beads from mouse Lineage Cell Depletion Kit (Miltenyi Biotec). CD11b+ Gr-1- BM 714 
cells from Rptor F/F, Mx1-Cre mice, Lin- CD11b+ PD-L1+ IMLECs / LSK / CLP / 715 
CMP populations from Raptor Ctrl/cKO or WT mice, CD11b+ Gr-1+ / CD11b- Gr-1- 716 
BM populations from Rptor F/F, Lyz2-Cre+/+ mice, CD11bhigh Gr-1- F4/80+ 717 
peritoneal macrophages were sorted using FACSAria II  or Influx™ cell sorter 718 
(BD Biosciences). The detailed information on Abs used in this study is in 719 
Supplementary file 3. 720 
 721 
BM cells transplantation 722 
C57BL/6 Ly5.2 (CD45.1+) recipient mice at the age of 6-12 weeks old were 723 
lethally irradiated for total 900-1,100 rads with a Cs-137 γ-ray source or a RS 724 
2000 X-ray irradiator (Rad Source Technologies, Inc.). Indicated donor BM cells 725 
(whole BM or FACS-sorted BM cells) were transplanted into recipients through 726 
the mice tail by intra-venous (i.v.) injection within 24 hours after irradiation 82. At 727 
different time points post-transplantation, peripheral blood from the recipient mice 728 
was analyzed by flow cytometry to test the reconstitutions. 729 
 730 
Conventional PCR and quantitative PCR 731 
Genomic DNA was isolated from BM cells by DNeasy Blood and Tissue Kit 732 
(Qiagen) as per manufacturer’s instructions. Total RNA was isolated using TRIzol 733 
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(Invitrogen) or ReliaPrep™ RNA Cell Miniprep System (Promega). Reverse 734 
transcription was carried out using random hemaxmer primers and SuperScript II 735 
Reverse Transcriptase (Invitrogen). Conventional PCR was performed using 736 
GoTaq Green Master Mix (Promega). Quantitative PCR (q-PCR) was performed 737 
by the 7500 real-time PCR system using Power SYBR Green Master Mixture 738 
(Applied Biosystems). Fold changes were calculated according to the ΔΔCT 739 
method 85. The primers used for conventional PCR and q-PCR are listed in 740 
Supplementary file 4. 741 
 742 
Ig gene rearrangement test by V(D)J analysis 743 
Immunoglobulin (Ig) gene recombination was determined using genomic DNA as 744 
previously described 86. For Heavy chain, a semi-nested PCR strategy was 745 
employed to amplify the framework regions of VH to specific sites of JH. First 746 
round amplification of 25 cycles was performed with primers FR/JH1 (70°C 747 
annealing/ 20 sec extension). Second round amplification of 35 cycles was with 748 
primers FR/JH2 (65°C annealing/ 30 sec extension). Light chain (Igk and Igl) 749 
recombination was tested by primers Vκ /Jκ5 and Vλ1 /Jλ1,3 following previous 750 
report 87. Sequences of primers used are listed in Supplementary file 4. 751 
 752 
OP9 cell co-culturing with HSPCs 753 
OP9 stromal cell line (ATCC Cat# CRL-2749, RRID:CVCL_4398) was purchased 754 
from American Type Culture Collection (ATCC, Manassas, USA). No cell lines 755 
used in this study were listed in the database of cross-contaminated or 756 
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misidentified cell lines suggested by International Cell Line Authentication 757 
Committee (ICLAC). All cell lines from ATCC were authenticated by the STR 758 
profiling method and tested as mycoplasma contamination free by ATCC. OP9 759 
cells were maintained in α-MEM medium (Life Technologies) supplemented with 760 
20% heat-inactivated fetal bovine serum (Hyclone), 100 units/ml of penicillin and 761 
100 µg/ml of streptomycin (Gibco). The 6-well and 12-well flat-bottomed plates 762 
were pre-coated with OP9 cells at approximate 100% confluence after overnight 763 
growth. Subsequently 2X103 LSK (Lin- c-Kit+ Sca-1+) or 5X104 CMP (Lin- c-Kit+ 764 
Sca-1- CD34MediumCD16/32Medium) cells or 5X104 CLP  (Lin- CD127+c-KitMedium Sca-765 
1Medium) cells FACS-sorted from Raptor Ctrl/cKO BM were seeded. The co-766 
culturing medium was additionally supplemented with 2ng/ml murine recombinant 767 
IL-3, 2ng/ml murine recombinant IL-6, 20ng/ml murine recombinant SCF, 768 
10ng/ml murine recombinant Flt3L and 5ng/ml murine recombinant IL-7 (all from 769 
R&D Systems). Lenti viral particles were produced in HEK 293T cells (ATCC 770 
Cat# CRL-3216, RRID:CVCL_0063) by transiently co-transfecting control vector 771 
pWPI (Plasmid #12254, Addgene), or pWPI-Myb (cDNA of Myb was purchased 772 
from DharmaconTM of GE Lifesciences, Catalog Number: MMM1013-202763262; 773 
Clone ID: 3672769) together with helper plasmids pMD2.G (Plasmid #12259, 774 
Addgene) and psPAX2 (Plasmid #12260, Addgene) using FuGENE® HD 775 
Transfection Reagent (Promega). OP9 cells were replaced every 3-4 days by 776 
transferring co-culturing cells to new plates pre-coated with fresh OP9 cells. The 777 
hematopoietic cells in suspension were harvested on day 10-14 post seeding 778 
and subjected to flow cytometric analyses. 779 
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 780 
TLR stimulation and inflammatory cytokine assay 781 
 For in vitro TLR stimulation, fresh BM cells were seeded in a 12-well plate with a 782 
density of 4X106 cells/ well(1ml medium/well) or in a 48-well plate with a density 783 
of 1X106 cells/ well (200μl medium/well). The culture medium was RPMI 1640 784 
(Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum 785 
(Hyclone), 100 units/ml of penicillin and 100 µg/ml of streptomycin (Gibco). BM 786 
cells were stimulated with 1μg/ml LPS (Sigma-Aldrich, from O111:B4 E.coli) or a 787 
panel of TLR agonists (InvivoGen) for 16 hours. For intracellular cytokine staining, 788 
the protein transport inhibitor Brefeldin A (eBioscience) was added to the 789 
culturing medium during the last 4 hours of incubation. 790 
 791 
The concentrations of the TLR agonists for in vitro studies were as following: 792 
TLR1/2-Pam3CSK4, 300ng/ml; TLR2-HKLM, 108 cells/ml; TLR3-pIpC(HMW), 793 
10μg/ml; TLR4-LPS-EK, 1μg/ml; TLR5-FLA-ST, 1μg/ml; TLR6/2-FSL-1, 100ng/ml; 794 
TLR7-ssRNA-DR/LyoVec, 1μg/ml; TLR9-ODN1826, 1μM. For in vivo tests, pIpC 795 
(GE Healthcare, 2 mg/kg), LPS (from O55:B5 E.coli, Sigma-Aldrich, 5 mg/kg) and 796 
Acetaminophen (Children’s TYLENOL, 3.2 mg/mouse) were injected i.p. 797 
Supernatant from in vitro cultured BM cells and serum from in vivo treated mice 798 
were assayed for inflammatory cytokines by BD Cytometric Bead Array (CBA)-799 
Mouse Inflammation Kit according to the manufacturer's protocols. 800 
 801 
cDNA library preparation and RNA sequencing  802 
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FACS-sorted CD11b+ Gr-1- BM cells from Raptor cKO mice and whole BM cells 803 
from Raptor Ctrl mice were used for RNA isolation with TRIzol Reagent (Life 804 
Technologies) per manufacturer’s instructions. The cDNA libraries were 805 
constructed following the standard Illumina protocols by TruSeq RNA and DNA 806 
sample preparation kits (Illumina). Briefly, beads containing oligo (dT) were used 807 
to isolate poly(A) mRNA from total RNA. Purified mRNA was then fragmented in 808 
fragmentation buffer. Using these short fragments as templates, random 809 
hexamer-primers were used to synthesize the first-strand cDNA. The second-810 
strand cDNA was synthesized using buffer, dNTPs, RNase H and DNA 811 
polymerase I. Short double-stranded cDNA fragments were purified for end 812 
repair and the addition of an ‘A’ base. Next, the short fragments were ligated to 813 
Illumina sequencing adaptors. DNA fragments of a selected size were gel-814 
purified and amplified by PCR. The amplified cDNA libraries were quality 815 
validated and then subjected to 50 nt single-end sequencing on an Illumina 816 
HiSeq 2000 at the University of Michigan DNA Sequencing Core. 817 
 818 
RNA-seq gene expression analysis 819 
The reference sequences used were genome and transcriptome sequences 820 
downloaded from the UCSC website (version mm10). Clean reads were 821 
respectively aligned to the reference genome and transcriptome using Tophat 822 
(RRID:SCR_013035)88.  No more than 2 mismatches were allowed in the 823 
alignment for each read. Reads that could be uniquely mapped to a gene were 824 
used to calculate the expression level. The gene expression level was measured 825 
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by the number of uniquely mapped reads per kilobase of exon region per million 826 
mappable reads (RPKM) and was calculated by DEGseq (RRID:SCR_008480)89. 827 
The formula was defined as below:    828 
in which C was the number of reads uniquely mapped to the given gene; N was 829 
the number of reads uniquely mapped to all genes; L was the total length of 830 
exons from the given gene. For genes with more than one alternative transcript, 831 
the longest transcript was selected to calculate the RPKM. 832 
 833 
PCA, differential and cell-specific expression analysis 834 
The RPKM method eliminates the influence of different gene lengths and 835 
sequencing discrepancies on the gene expression calculation. Therefore, the 836 
RPKM value can be used for comparing the differences in gene expression 837 
among samples. The RPKM value of all RNA-seq raw data were calculated 838 
according to the same workflow as stated above.  839 
 840 
A function was implemented in the R software to perform principal component 841 
analysis (PCA). This function computes the eigenvalues and eigenvectors of the 842 
dataset (23498 genes) using the correlation matrix. The eigenvalues were then 843 
ordered from highest to lowest, indicating their relative contribution to the 844 
structure of the data. The projection of each sample defined by components was 845 
represented as a dot plot to generate the PCA figures.  846 
 847 
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Selected samples were then pooled by subtypes and a two sided t-test with FDR 848 
(False discovery rate) of 0.05 and fold change of 4 was performed to identify 849 
differentially expressed genes between IMLECs and other subtypes (mean 850 
RPKM values of genes in two subtypes both below 5 were deleted). For subtype-851 
specific genes identified, a one-sided t-test (null hypothesis is greater) was 852 
performed with FDR of 0.01 and fold change of 4 contrasting each subtype in 853 
turn versus all other subtypes pooled, and statistically significant genes were 854 
assigned to the respective subtype signature.  855 
 856 
RNA-seq datasets in this study have been deposited in the Gene Expression 857 
Omnibus (GEO) database as accession number GSE67863. Other public RNA-858 
seq datasets used are as followings: peritoneal CD11b+F4/80+ macrophages 859 
(GSM1103013, GSM1103014 in GEO Series GSE45358); normal BM CD11b+ 860 
Gr-1+ granulocytes (GSM1166354, GSM1166355, GSM1166356 in GEO Series 861 
GSE48048); BM-derived dendritic cells (GSM1012795, GSM1012796 and 862 
GSM1012797 in GEO Series GSE41265); BM erythroid cells (GSM1208164, 863 
GSM1208165 and GSM1208166 in GEO Series GSE49843 ); BM pro B and pre 864 
B cells (GSM978778 and GSM978779 in GEO Series GSE39756); Naïve B cells 865 
(GSM1155172, GSM1155176, GSM1155180 and GSM1155184 in GEO Series 866 
GSE47703); activated B cells (GSM1155170, GSM1155174, GSM1155178 and 867 
GSM1155182 in GEO Series GSE47703); CD4 T cells, CD8 T cells and natural 868 
regulatory T (nTreg) cells (GSM1169492, GSM1169501, GSM1169493, 869 
GSM1169502, GSM1169499 and GSM1169508 in GEO Series GSE48138); . 870 
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Spleen NK cells (GSM1257953, GSM1257954, GSM1257955 and GSM 1257956 871 
in GEO Series GSE52047); Blood neutrophils (GSM1340629, GSM1340630, 872 
GSM1340631 and GSM1340632 in GEO Series GSE55633); Lung basophils and 873 
eosinophils (GSM1358432, GSM1358433, GSM1358436 and GSM1358437 in 874 
GEO Series GSE56292). RNA-seq data on ex vivo DC subsets are obtained 875 
from GEO Series GSE62704: GSM1531794 (CDP), GSM1531795 (pDC), 876 
GSM1531796 (preDC), GSM1531797 (DN DC), GSM1531798 (CD4+ DC), 877 
GSM1531799 (CD8+ DC). 878 
Genome browser display of immunoglobulin expression 879 
To facilitate the global viewing of transcript structure and gene expression 880 
quantity of immunoglobulin, an interface in which RNA-seq gene expression of 881 
immunoglobulin can be viewed in Genome Browser display was constructed. For 882 
viewing and analysis, the UCSC Genome Browser (http://www.genome.ucsc.edu, 883 
RRID:SCR_005780) 90 with the mm10 version of the mouse genome was used. 884 
For each base in each cell type, the normalized number of aligned reads count 885 
was defined as below:  886 
 887 
 888 
in which N was the number of reads uniquely mapped to the given base in each 889 
cell type ; n was the number of replicates for each cell type samples; A was a 890 
constant t in which takes the value of 3.5E+7. The normalized number of aligned 891 
reads count for each base in each cell type was stored as WIG file and was 892 
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uploaded to UCSC genome browser. For each track, y-axis depicted the 893 
normalized number of aligned reads count and x-axis depicts physical distance in 894 
bases along the chromosome. 895 
 896 
Statistical analysis 897 
All the data are presented as mean ± SD. Unless otherwise indicated, two-tailed, 898 
unpaired student’s t tests were used for comparison between two experimental 899 
groups.  In Figure 8I and Figure 8J, where the data do not follow normal 900 
distribution, Mann-Whitney tests were used. The log-rank tests were used for the 901 
Kaplan-Meier survival analysis. Statistical significance was determined as p<0.05 902 
(*, p<0.05; **, p<0.01; ***, p<0.001). 903 
 904 
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Figure Legends 1134 
Figure 1 Targeted mutation of Rptor in hematopoiesis led to massive 1135 
accumulation of IMLEC.  1136 
(A) Schematic of experimental design.  Sex-matched 6-8 weeks old Ctrl (Rptor 1137 
F/F) and cKO (Rptor F/F, Mx1-Cre) mice were treated with pIpC for 7 times. The 1138 
phenotypes were analyzed on day 7 or day 30 after the complement of pIpC 1139 
treatment. (B) Representative flow cytometric analysis of myeloid cells from mice 1140 
BM by CD11b and Gr-1 on day 7 after pIpC treatment. Similar data were 1141 
obtained on day 30. (C) Frequencies of various hematopoietic cell populations in 1142 
BM based on CD11b and Gr-1 markers. n=7 for Ctrl mice; n=9 for cKO mice. 1143 
Data are pooled from 3 independent experiments. (D) Expansion of lymphoblast 1144 
population in cKO BM revealed by histology. Left, H&E staining showing 1145 
prominence of cells with lymphoid morphology in the cKO BM; Right, normal BM 1146 
histology from Ctrl mouse showing normal myeloid and erythroid lineages. Scale 1147 
bar, 20 m. (E) Expansion of lymphoblast revealed by cytology. Left, cytological 1148 
preparation of BM smear from cKO mouse showing preponderance of 1149 
lymphocytes (short arrows) and severe depletion of myeloid and erythroid 1150 
lineages. There were some promyelocytes and myelocytes present (larger cells) 1151 
but no mature neutrophils. Right, normal cytological preparation of BM from Ctrl 1152 
mouse. There were numerous erythroid precursors with intensely basophilic, 1153 
condensed chromatin (arrowheads) and a few lymphocytes (short arrow) with 1154 
less condensed chromatin. Additionally, in BM there were numerous mature 1155 
neutrophils (ringed nucleus with constrictions) which were not severely depleted 1156 
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in the cKO mouse. Scale bar, 10 m.  (F) Giemsa staining of FACS-sorted Rptor-1157 
deficient CD11b+Gr-1- BM cells. Scale bar, 10μm. Similar morphology was 1158 
observed in three independent experiments. (G) Principal component analysis 1159 
(PCA) of gene expression in CD11b+ Gr-1- BM cells (IMLECs) and other 1160 
hematopoietic cells. Numbers along axes indicate relative scaling of the principal 1161 
variables.  RNA-seq data from IMLECs obtained in our study were compared 1162 
with those deposited in public database by others.  Datasets are from known 1163 
lymphoid (Pro-B, Pre-B, Naïve B, CD4 T, CD8 T, Treg and NK) or myeloid 1164 
(macrophage, dendritic cell, granulocyte, neutrophil, eosinophil, basophil and 1165 
erythrocyte) subsets. 1166 
 1167 
Figure 2  Unique gene signature of Rptor -/- CD11b+ Gr-1- BM IMLECs.  1168 
(A) Heat map representing the relative expression levels for indicated population-1169 
specific genes. Genes up-regulated for at least 4-fold with FDR-adjusted p-value 1170 
<0.01 were considered population-specific. Numbers on right indicate amounts of 1171 
population-specific genes. (B) Heat map representing expression levels of 48 1172 
CD11b+Gr-1- BM IMLEC-specific genes among indicated populations including 1173 
macrophage, B precursor, naive B and granulocyte. (C) Genome browser display 1174 
of transcript structure and gene expression quantity for immunoglobulin heavy 1175 
chain (IgH) complex gene region from indicated populations. For each track, the 1176 
normalized numbers of aligned reads count or Reads Per Kilobase of transcript 1177 
per Million mapped RNA (RPKM) are shown in y-axis, while the gene positions 1178 
for the sterile transcripts are shown in x-axis.  Numbers on top indicate the start 1179 
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and end loci on bases along chromosome 12 for specified gene region. Similar 1180 
profiles of cKO IMLEC were observed in two other samples analyzed. (D) mRNA 1181 
levels of Rag1 and Rag2 in cKO CD11b+ Gr-1- BM IMLECs in comparison to Ctrl 1182 
whole BM cells. n=6 for Ctrl-WBM; n=8 for IMLEC. Data are pooled from 3 1183 
independent experiments.  (E) IMLECs did not display immunoglobulin gene 1184 
rearrangement. FACS-sorted CD11b+ Gr-1- cells (IMLECs) from cKO BM were 1185 
dissected for Ig gene rearrangement patterns of heavy chain (JH), light chains Igk 1186 
(JLκ) and Igl (JLλ) by PCR. WBM cells from Raptor Ctrl mice were used as positive 1187 
control.  These data have been repeated twice. 1188 
 1189 
Figure 3 Identification of IMLEC by cell surface markers in both Raptor cKO 1190 
and WT mice.  1191 
(A) IMLECs do not express surface markers for conventional lymphocytes (CD3, 1192 
B220 and NK1.1) and stem and progenitor cells (c-Kit and Sca-1). CD11b+ Gr-1- 1193 
IMLECs from Raptor cKO BM were tested for their expression of lymphocytes 1194 
and progenitor cell markers. These data have been repeated 3 times. (B) 1195 
IMLECs do not express markers for monocytes and macrophages but 1196 
surprisingly express high levels of PD-L1. Filled gray areas indicate distributions 1197 
of fluorescence from stainings by control antibodies. One representative result of 1198 
at least five experiments is shown. (C) Rptor deletion causes expansion of Lin- 1199 
(B220- CD3- Ter119- NK1.1- Gr-1- F4/80- CD115- ) CD11b+ PD-L1+ IMLECs in BM. 1200 
Representative flow staining profiles for BM IMLECs (left) and their abundance 1201 
summary data (right) are presented. n=5 for Ctrl BM; n=5 for cKO BM. (D) Lin-1202 
 49 
CD11b+ PD-L1+ BM IMLECs are CD11c-/low. One representative result of two 1203 
experiments is shown. (E) The Lin- CD11b+ PD-L1+ CD11c-/low IMLECs are found 1204 
in various lymphoid and non-lymphoid organs from WT mice.  mLN, mesenteric 1205 
lymph nodes; c/i LN, cervical and inguinal lymph nodes. The numbers (Mean±SD) 1206 
are summarized abundances of IMLECs among mononuclear cells (MNCs) from 1207 
3 WT mice. (F-H) Rptor deletion caused a broad accumulation of IMLECs in lung 1208 
(F), mesenteric lymph nodes (G) and peripheral (cervical and inguinal) lymph 1209 
nodes (H). Results shown are representative of three mice in each group. (I) 1210 
Summary data showing increased IMLECs in the peripheral blood, lymphoid and 1211 
non-lymphoid organs. n=3 for both groups.  1212 
 1213 
Figure 4 Comparison of IMLECs identified in both WT and Raptor-deficient 1214 
BM.  1215 
(A) Giemsa staining of Lin- CD11b+ PD-L1+ IMLECs from WT BM and Rptor-cKO 1216 
BM. One representative result of 3 independent experiments is shown. Scale bar, 1217 
10μm.  (B) Size and granularity of IMLECs from Raptor Ctrl and cKo BM were 1218 
evaluated by FSC and SSC, respectively. n=5 for each group. (C) IMLEC from 1219 
WT BM expresses sterile transcripts from the Igh and Igl loci. Ig transcript levels 1220 
in macrophage are artificially defined as 1. (D) Heat map representing the 1221 
relative expression levels for indicated population specific transcription factor 1222 
genes. Genes up-regulated for at least 4-fold with FDR-adjusted p-value<0.01 1223 
were considered population-specific. (E) IMLECs from both WT and Raptor-cKO 1224 
BM exhibited high levels of mRNA transcripts for the specified transcription 1225 
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factors (Mitf, Atf3 and Zdhhc1). n=5 for each group. (F, G)  Ctrl and cKO IMLECs 1226 
are non-cycling cells in contrast to Lin+ BM cells. (H, I) IMLECs are prone to 1227 
apoptosis based on their binding to Annexin V. Results in (C), (G) and (I) 1228 
represent one of 2 independent experiments with each involving 3 mice per 1229 
group.   1230 
 1231 
Figure 5 Raptor represses differentiation of IMLEC from CMP.   1232 
(A, B) IMLEC accumulation in Rptor-/- BM is cell autonomous.  (A) Diagram 1233 
depicting generation of mixed BM chimera, induction of Rptor deletion and 1234 
analyses for IMLEC. (B) In mixed BM chimera mice, IMLEC was accumulated 1235 
only in the Raptor-deficient hematopoietic cells. Mice were sacrificed and 1236 
analyzed at 4 weeks post pIpC treatment. CD45.1+ and CD45.2+ donor-derived 1237 
BM cells were gated to show the myeloid subsets based on CD11b and Gr-1.  1238 
Similar data were obtained in 3 independent experiments, each involving at least 1239 
3 mice per group. (C, D) BM IMLECs are not converted from CD11b+ Gr-1- 1240 
granulocytes. (C) Genotyping and deletion efficacy.  CD11b+Gr-1+ cells (DP) and 1241 
CD11b-Gr-1- cells (DN) were sorted from BM of KO (RptorF/F, Lyz2-Cre+/+) mice. 1242 
Floxed and deleted Rptor alleles, as well as Lyz2-Cre wild type (WT) and 1243 
mutated (MT) alleles were confirmed by PCR.  (D) Efficient deletion of Rptor in 1244 
the CD11b+Gr-1+ compartment failed to cause IMLEC accumulation.  Data 1245 
shown are representative BM flow profiles of Ctrl mice and those with Rptor 1246 
deletion in the CD11b+Gr-1+ compartment, depicting distributions of CD11b and 1247 
Gr-1 markers in adult mice.  Similar data have been obtained in 3 experiments, 1248 
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involving a total of 5 mice per group. (E, F) Rptor-/- LSK, CLP and CMP cells 1249 
differentiate into IMLECs in vitro. (E) Diagram of experimental design. 2X103 LSK 1250 
cells or 5X104 CLP or 5X104 CMP cells were co-cultured with the OP9 cells for 1251 
10 days.  (F) Rptor deletion promoted generation of IMLEC. The CD45.2+ 1252 
leukocytes were gated and analyzed for their expression of CD11b, Gr-1 and PD-1253 
L1. Data shown are representative of three independent experiments. (G, H) 1254 
Both LSK and CMP cells differentiate into IMLECs in vivo. (G) Diagram of BM 1255 
cells transplantation. FACS-sorted, Ctrl or cKO LSK cells (5X104/mouse) or CMP 1256 
cells (1.2 X105/mouse) were injected i.v. to CD45.1 recipient mice which were 1257 
immediately administrated with 5 daily pIpC treatments.  BM cells were harvested 1258 
on day 7 for FACS analyses. (H) Rptor deletion promoted differentiation of 1259 
progenitor cells into IMLEC. Donor-derived CD45.2+ BM cells were gated to 1260 
analyze surface markers CD11b, Gr-1 and PD-L1. Data shown are 1261 
representative flow profiles from one of 3 independent experiments. 1262 
 1263 
Figure 6 Inactivation of Myb is an underlying cause for accumulation of 1264 
IMLEC.  1265 
(A) Reduction of Myb mRNA in the Rptor-deficient HSPCs.  BM LSK and CMP 1266 
populations were FACS-sorted from Ctrl and cKO mice at 1-3 weeks after pIpC 1267 
treatment. Quantitation of Myb mRNA was performed by qPCR. n=5 for Ctrl-LSK; 1268 
n=4 for cKO-LSK (left). n=4 for Ctrl-CMP; n=3 for cKO-CMP (right). (B) Detection 1269 
of c-Myb protein by intracellular staining.  Data represent one of three 1270 
independent experiments with similar results. (C-E) Deletion of c-Myb in mice 1271 
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with homozygous floxed Myb resulted in enhanced generation of IMLECs. (C) 1272 
Schematic of experimental design.  Sex-matched 6-8 weeks old c-Myb Ctrl (Myb 1273 
F/F) and cKO (Myb F/F, Mx1-Cre) mice were treated with pIpC for 7 times. The 1274 
phenotypes were analyzed on day 7 after the complement of pIpC treatment. 1275 
Inducible deletion of c-Myb showed obvious increase of PD-L1 expression on 1276 
CD11b+Gr-1- BM cells (D) and production of IMLECs (E). n=3 for c-Myb Ctrl mice; 1277 
n=3 for c-Myb cKO mice. (F-H) Deletion of Myb enhances generation of IMLEC. 1278 
(F) Diagram of experimental design. Whole BM cells (2X106/mice) of given 1279 
genotypes were used for transplantation. Once the chimera mice were 1280 
established, deletion of Myb was induced by five daily injection of tamoxifen. (G) 1281 
Detection of Myb deletion in the whole BM cells after tamoxifen treatments.  Data 1282 
are representative of two independent experiments. (H) Generation of IMLEC is 1283 
promoted by inactivation of Myb.  BM cells were harvested at 7 days after first 1284 
tamoxifen treatment and analyzed for IMLECs based on surface markers CD11b, 1285 
Gr-1 and PD-L1 within the donor-derived CD45.2+ BM cells. Data shown 1286 
represent one of three experiments using either first or second generation of BM 1287 
chimeras. (I) Rptor deletion broadly increases miRNAs targeting Myb. Lin- c-Kit+ 1288 
HSPCs were isolated from Raptor Ctrl and cKO mice at 10 days after pIpC 1289 
treatment. miRNA levels were measured by miRNA microarray. The y-axis 1290 
shows the log2 ratio of signal, while the x-axis shows the -log10P value. The doted 1291 
boxes show the numbers of significantly (P<0.05) up-regulated (fold change>2) 1292 
or down-regulated (fold change <0.5) miRNAs among 50 miRNAs with mirSVR 1293 
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score < -1.0. Each dot represents the mean value of a unique miRNA from 3 1294 
independent samples.  1295 
 1296 
Figure 7 IMLECs broadly express PPRs and produce large amounts of 1297 
inflammatory cytokines upon stimulation by various TLR ligands. 1298 
(A) Heat map showing the relative transcript levels of TLRs among the indicated 1299 
populations. (B) Both WT and Raptor-cKO IMLECs have greatly elevated 1300 
expression of multiple TLRs genes in comparison to Ctrl BM. q-PCR was 1301 
performed to determine transcript levels of Tlr1-9 genes.  After normalizing for 1302 
cDNA input based on Hprt mRNA in each sample, the Tlr1-9 levels in the FACS-1303 
sorted cKO CD11b+ Gr-1- BM IMLEC were compared with Ctrl BM (artificially 1304 
defined as 1.0).  n=3 for Ctrl WBM; n=5 for cKO- IMLEC; n=5 for WT-IMLEC. 1305 
Similar results were obtained using mice sacrificed at 2 weeks ~ 2 months after 1306 
pIpC treatment. (C, D) In responses to various TLR ligands, Rptor cKO BM cells 1307 
produced greatly elevated amounts of TNF-α (C) and MCP-1 (D) than the Ctrl 1308 
BM. Data shown are from one experiment involving 3 repeats per group and 1309 
have been reproduced in five independent experiments. (E) Lin- (B220-CD3-1310 
Ter119-Gr-1-NK1.1-F4/80-CD115- ) CD11b+ PD-L1+ IMLECs from both cKO and 1311 
WT BM were robust TNF-α producers after stimulation with LPS.  BM cells 1312 
(1X107 cells / well) were stimulated with LPS (1μg/ml) for 16 hours with the 1313 
presence of Golgi blocker in the last 4 hours. Data shown are representative 1314 
profiles from one experiment and have been reproduced in 3 independent 1315 
experiments. 1316 
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 1317 
 1318 
Figure 8   Rptor cKO mice are hyper sensitive to challenges by TLR ligands.   1319 
(A) High blood levels of inflammatory cytokines in cKO mice that have received 7 1320 
pIpC treatments. Serum samples collected at 7 days after the last pIpC treatment 1321 
were tested for levels of IL-12p70, TNF-α, IFN-γ, MCP-1, IL-10 and IL-6. Dot 1322 
plots depict cytokine levels in individual cKO (red dots) or Ctrl (blue dots) mice, 1323 
and line drawings depict means and SD.  n=12 for Ctrl mice and n=11 for cKO 1324 
mice.  (B) High proportions of Rptor cKO mice that received 7 pIpC injections 1325 
died within 7 weeks after first pIpC treatment. Data shown are Kaplan-Meier 1326 
survival curve, and the statistical significance is determined by log-rank test. 1327 
n=32 for Ctrl mice and n=31 for cKO mice.   (C) Representative H&E staining of 1328 
liver sections from Rptor Ctrl and cKO mice at 2 weeks post pIpC treatment. 1329 
Scale bars represent 200μm (10X) and 50μm (40X), respectively. (D, E) Massive 1330 
accumulation of IMLEC in cKO liver.  (D) Accumulation of CD11b+ Gr-1- cells in 1331 
the cKO liver.  (E) CD11b+ Gr-1- cells in cKO livers demonstrated IMLEC surface 1332 
markers, including PD-L1high and F4/80low/-.  Gray lines indicate the staining for 1333 
isotype control antibodies.  Results are representative of at least five 1334 
independent analyses. (F-H) cKO mice are vulnerable to low doses of LPS 1335 
challenges. At 2-3 months after pIpC treatments, cKO and Ctrl mice were 1336 
challenged with 5mg/kg body weight of LPS and observed survival.  (F) Kaplan- 1337 
Meier survival analysis. Data are pooled from 3 independent experiments. n=14 1338 
for Ctrl mice; n=11 for cKO mice. Inflammatory cytokines TNF-α (G) and MCP-1 1339 
(H) levels from mice serum before (0h) and at 6 hours after (6h) LPS injection are 1340 
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shown. n=10 for Ctrl mice; n=9 for cKO mice. Note greater than 500-fold increase 1341 
in plasma TNF- levels. (I, J) cKO mice mounted enhanced inflammatory 1342 
response to acetaminophen-triggered liver necrosis. Serum TNF- (I) and MCP-1343 
1(J) levels at 6 hours upon acetaminophen (3.2 mg/mouse) treatment are shown. 1344 
n=4 for Ctrl mice; n=6 for cKO mice. Mann-Whitney test was used for statistics 1345 
analysis, and lines indicate Mean ±SD.  Similar trends were observed in another 1346 
independent experiment. 1347 
 1348 
Figure 9 Rptor deletion in hematopoietic cells greatly increased 1349 
vulnerability of mice to pIpC.   1350 
(A) Diagram of experimental design. WT CD45.1+ recipient mice were irradiated 1351 
and transplanted with 5X106 BM cells from RptorF/F and RptorF/F, Mx1-Cre BM. 1352 
After the fully reconstitution, recipients were treated with pIpC 3 times every other 1353 
day to induce gene deletion in chimera mice with cKO BM. 10 days after the last 1354 
injection of pIpC, recipients were challenged with another pIpC injection and the 1355 
survival of mice were followed for 4 more weeks. Arrows denote the injections of 1356 
pIpC at indicated time points.  (B) Kaplan-Meier survival analysis after pIpC 1357 
treatments. n= 12 for Ctrl chimera mice; n=15 for cKO chimera mice. (C) 1358 
Histological analysis of liver sections after H&E staining.  Note extensive 1359 
inflammation and liver damage in cKO chimera mice. Scale bars represent 1360 
200μm (10X), 100μm (20X) and 50μm (40X). (D-F) Identification of IMLEC in BM 1361 
(D), spleen (E) and livers (F) by flow cytometry. Mice were euthanized 45 days 1362 
after the first pIpC injection. The distinct CD11b+ Gr-1- PD-L1+ F4/80low/- IMLECs 1363 
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greatly enriched in BM, spleen and liver of recipients of Rptor cKO BM. FACS 1364 
profiles shown represent one of five independent experiments.   1365 
 1366 
 1367 
Figure Supplements and Supplementary Files 1368 
 1369 
Figure 1—figure supplement 1 Conditional deletion of Rptor resulted in 1370 
abnormal hematopoiesis.  1371 
(A) Deletion of Rptor in BM cells. PCR were performed to check the deletion in 1372 
BM from mice 2 weeks after pIpC treatment (for Ctrl and cKO mice, no treatment 1373 
for WT mice). (B) Representative pictures of leg bones (tibiae and femurs), 1374 
spleen, and thymus harvested from mice on day 30 post pIpC treatment. (C) 1375 
Histology findings in the cKO spleen by H&E staining. Up left panel: a spleen 1376 
histological section showing expanded white pulp areas (WP) and compressed 1377 
intervening red pulp (RP). The white pulp contains an increased population of 1378 
lightly staining cells that sometimes is situated in the marginal zones and 1379 
follicular centers (B cell areas) and sometimes infiltrates the periarteriolar 1380 
sheaths (T cell area, long arrow). Up right panel: normal splenic architecture from 1381 
control mouse. Scale bar, 200 m. Down left panel: higher magnification of 1382 
expanded cell population within the splenic white pulp. Morphologically these 1383 
cells resemble germinal center lymphocytes. There are both smaller cells with 1384 
cleaved nuclei (long arrow) resembling centrocytes and larger cells with 1-2 1385 
prominent nucleoli resembling centroblasts (short arrow). There are small 1386 
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numbers of plasmacytoid cells (arrowhead). Down right panel: histological 1387 
section of splenic red pulp Red pulp of the spleen showing foci of extramedullary 1388 
hematopoiesis with decreased erythroid (short arrow) and myeloid (long arrow) 1389 
progenitors. The erythroid lineage contains occasional foci of pyknotic or 1390 
karyorrhectic (fragmented) nuclei consistent with cell death (asterisk). Scale bar, 1391 
20 m. (D) The cellularities of splenocytes (left) and thymocytes (right) from mice 1392 
at day 30 post pIpC treatment. n=6 for Ctrl mice; n=5 for cKO mice. (E) BM 1393 
cellularities (left) and spleen/body weight ratios (right) for mice on day 7 and day 1394 
30 after pIpC treatment. n=3~8 for Ctrl mice; n=5~6 for cKO mice.  1395 
 1396 
Figure 1—figure supplement 2 Raptor deletion led to impaired 1397 
developments of B lymphoid, erythroid and myeloid compartments in BM.  1398 
(A) Representative FACS profiles for Pro B (CD127+B220+BP-1-IgM-IgD- cells), 1399 
Pre B ( CD127+B220+BP-1+IgM-IgD- cells), Immature B (CD127-B220+BP-1-1400 
IgM+IgD- cells), Mature B (CD127-B220+BP-1-IgM+IgD+ cells) in mice BM on day 1401 
7 after pIpC treatment. (B) Frequencies of BM B cells subsets as in (A). n=5 for 1402 
Ctrl mice and n=6 for cKO mice. (C) Representative FACS analysis of erythroid 1403 
populations in BM by Ter119 and CD71. Roman numerals and numbers indicate 1404 
the identity and percentages of the developmentally defined subpopulations: I, 1405 
proerythroblasts; II, basophilic erythroblasts; III, polychromatophilic erythroblasts; 1406 
IV, orthochromatophilic erythroblasts. (D) Frequencies of erythroblast subsets in 1407 
mice BM. n=5 for Ctrl mice and n=6 for cKO mice. (E, F) Size and granularity of 1408 
BM CD11b+ Gr-1- IMLECs from Rptor cKO mice. (E) Flow cytometric assays for 1409 
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size and granularity of Ctrl  and cKO BM cells by FSC and SSC, respectively. 1410 
Erythroid cells with smaller size and granularity were excluded in the initial gating. 1411 
DP (double positive) represents CD11b+ Gr-1+ granulocytes, and DN (double 1412 
negative) represents (CD11b- Gr-1-) cells. (F) Relative size (FSC-A) and 1413 
granularities (SSC-A) of DN, DP and IMLEC.  The mean values in Ctrl mice are 1414 
artificially defined as 100%. n=5 for Ctrl mice; n=3 for cKO mice. 1415 
 1416 
Figure 1—figure supplement 3 Rptor cKO mice are pancytopenic.   1417 
(A) Complete blood cell counts (CBC) data for Ctrl and cKO mice on day 30 after 1418 
pIpC treatment. WBC, white blood cells; NE, neutrophils; LY, lymphocytes; MO, 1419 
monocytes;  RBC, red blood cells; Hb, hemoglobin; PLT, platelets. Means of the 1420 
Ctrl mice in each experiment are artificially defined as 100%. (B) Representative 1421 
FACS profiles showing the percentages of different leukocyte populations in 1422 
peripheral blood from Ctrl and cKO mice on day 30 after pIpC treatment. (C, D) 1423 
Reduction of leukocyte populations in the peripheral blood of cKO mice. 1424 
Frequencies among CD45.2+ leukocytes (C) and absolute numbers (D) of 1425 
various cell types in blood on day 30 after pIpC treatment are shown. n=7 for Ctrl 1426 
mice; n=6 for cKO mice. Data represent one of three independent experiments 1427 
with similar results. 1428 
 1429 
Figure 1—figure supplement 4 Rptor deletion increased hematopoietic 1430 
stem and progenitor cells in BM.  1431 
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(A) Representative FACS profiles for Lin- Sca-1+ c-Kit+ cells (LSK, identified as 1432 
CD3- B220- Ter119- CD11b- Gr-1- Sca-1+ c-Kit+ cells), multipotent progenitor cells 1433 
(MPP, identified as Lin- Sca-1+ c-Kit+ CD150- CD48+ cells), short-term HSC (ST-1434 
HSC, identified as Lin- Sca-1+ c-Kit+ CD150+ CD48+ cells) and long-term HSC (LT-1435 
HSC, identified as Lin- Sca-1+ c-Kit+ CD150+ CD48- cells) in the BM from Raptor 1436 
Ctrl and cKO mice on day 7 after pIpC treatment. Numbers indicate the 1437 
percentages of gated populations in total BM cells. (B) Frequencies (left) and 1438 
absolute numbers (right) of stem and progenitor cells as in (A) are shown. n=6 for 1439 
Ctrl mice; n=7 for cKO mice. (C) Representative FACS profiles for common 1440 
myeloid progenitor (CMP, identified as Lin- Sca-1- c-Kit+ CD34MediumCD16/32Medium 1441 
cell), granulocyte / macrophage progenitor (GMP, identified as Lin- Sca-1- c-Kit+ 1442 
CD34+ CD16/32 + cell) and megakaryocyte / erythroid progenitor (MEP, identified 1443 
as Lin- Sca-1- c-Kit+ CD34- CD16/32- cell ) in BM. (D) Frequencies (left) and 1444 
absolute numbers (right) of myeloid progenitors as in (C) are shown. n=5 for Ctrl 1445 
mice; n=5 for cKO mice. 1446 
 1447 
Figure 1—figure supplement 5 Tamoxifen induced conditional deletion of 1448 
Rptor in hematopoiesis also led to massive accumulation of IMLECs.  1449 
(A) Schematic of experimental design. Sex-matched 6-8 weeks old Ctrl (Rptor F/F) 1450 
and cKO (Rptor F/F, CreER) mice were treated with Tamoxifen for 5 consecutive 1451 
days. The phenotypes were analyzed 3 weeks after the first treatment. (B) 1452 
Representative flow cytometric analysis of myeloid cells from Ctrl and cKO mice 1453 
BM by CD11b, Gr-1 and PD-L1. (C) Rptor deletion caused expansion of Lin- 1454 
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(B220- CD3- Ter119- NK1.1- Gr-1- F4/80- CD115- ) CD11b+ PD-L1+ IMLECs in 1455 
BM. (D) Schematic of experimental design. CD45.2+ Ctrl BM and cKO BM were 1456 
transplanted into lethal dose irradiated CD45.1+ recipient mice. Tamoxifen 1457 
treatment of recipient mice was started 6 weeks after fully reconstitution of donor-1458 
derived cells. The phenotypes were analyzed 3 weeks after the first treatment. (E, 1459 
F) Representative flow cytometrical profiles of donor-derived CD45.2+ Myeloid 1460 
cells (E) and IMLECs (F) in BM of recipient mice are shown as in (B) and (C), 1461 
respectively. 1462 
 1463 
Figure 2—figure supplement 1 In silico pair wise comparisons between 1464 
IMLECs and other closely related leukocytes based on our RNA-seq data 1465 
and the publically available RNA-seq data.  1466 
(A-D)Based on the space proximity in the PCA data, macrophage (A), B 1467 
precursor (B), naive B (C) and granulocyte (D) were selected for one-to-one 1468 
comparison. Numbers in corners indicate amounts of genes significantly (FDR-1469 
adjusted p-value<0.05) up-regulated (right) or down-regulated (left) by at least 4-1470 
fold. (E, F) IMLECs in Raptor cKO BM are distinct from all DC subsets tested. (E) 1471 
Principal component analysis (PCA) of gene expression in Raptor cKO CD11b+ 1472 
Gr-1- BM cell (IMLEC), macrophage, B precursors and various ex vivo DC 1473 
subsets. Numbers along axes indicate relative scaling of the principal variables.  1474 
(F) Clustering of IMLEC, macrophage, B precursors with other DC subsets based 1475 
on their gene expression profiles. Hierarchical clustering with complete linkage 1476 
was carried out using the R software. The public RNA-seq datasets for DC 1477 
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subsets used are as followings: CDP (common DC precursor, GSM1531794); 1478 
pDC (GSM1531795); preDC (GSM1531796); DN DC (CD4 and CD8 double 1479 
negative DC, GSM1531797); CD4+ DC (GSM1531798) and CD8+ DC 1480 
(GSM1531799).  1481 
 1482 
Figure 2—figure supplement 2 cKO IMLECs have a similar expression 1483 
patterns as that of B-lymphoid subsets in the sterile transcripts from Igk 1484 
and Igl loci. 1485 
(A, B) Genome browser display of transcript expression of Igk locus in 1486 
chromosome 6 (A) and Igl locus in chromosome 16 (B). For each track, the y-1487 
axis is the normalized number of aligned reads counts of gene region, whereas 1488 
the x-axis depicts physical distance in base-pairs (bp). Numbers on top indicate 1489 
the start and end positions of specified gene regions. 1490 
 1491 
Figure 4—figure supplement 1 Comparisons of surface markers, viability 1492 
and cellular proliferation among IMLECs and other defined lineages. 1493 
(A) IMLECs from Raptor Ctrl and cKO BM displayed comparable expression 1494 
levels of MHC-I, MHC-II and other surface markers (Ly6C, CD14 and CD68). 1495 
Data shown are representative of 3 independent experiments. (B, C) IMLECs 1496 
from Raptor Ctrl and cKO BM exhibited much slower proliferation than other BM 1497 
lineages. Representative flow profile (B) and summary data (C) are from BrdU 1498 
incorporation assays. (D, E) IMLECs from Raptor Ctrl and cKO BM were more 1499 
prone to apoptosis than other BM lineages. Representative flow profile (D) and 1500 
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summary data (E) are from Annexin V and 7-AAD staining. B cells, B220+ BM 1501 
cells; T cells, CD3+ BM cells; Granulocytes, CD11b+Gr-1+ BM cells. n=5 for Ctrl 1502 
mice; n=5 for cKO mice. 1503 
 1504 
Figure 6—figure supplement 1 c-Myb expression and accumulation of 1505 
IMLECs. (A-C) Induced deletion of c-Myb in mice with heterozygous floxed c-1506 
Myb (Myb F/+, Mx1-Cre) did not show significant accumulation of IMLECS in 1507 
mouse BM. (A) Schematic of experimental design.  Sex-matched 6-8 weeks old 1508 
Ctrl (Myb F/+) and heterozygous floxed c-Myb (Myb F/+, Mx1-Cre) mice were 1509 
treated with pIpC for 7 times. The phenotypes were analyzed on day 7 after the 1510 
complement of pIpC treatment. (B) Representative flow profile of BM IMLECs. (C) 1511 
Detection of Myb deletion in the whole BM cells after pIpC treatment. Data in (B) 1512 
and (C) are representative results of independent experiments with 3 groups of 1513 
paired mice. (D-G)The provision of heterologous c-Myb significantly diminished 1514 
the generation of IMLECs from Raptor-deficient LSK cells. (D, E) Myb-expression 1515 
lenti-virus (pWPI-Myb) was validated by intracellular staining (D) and western blot 1516 
(E) of CHO cells 36 hours after virus infection. Lenti-virus with GFP co-1517 
expression (pWPI) was used as control. AF568, Alexa Fluor 568 dye. (F) 1518 
Diagram of experimental design. 1X104 LSK cells sorted from pIpC treated 1519 
Raptor cKO mice were infected with indicated lenti-virus and subsequently co-1520 
cultured with the OP9 cells for 12 days. (G) GFP+ cells with heterologous c-Myb 1521 
expression did not give rise to CD11b+ Gr-1- PD-L1+ IMLECs. Data represent the 1522 
results of two independent experiments. 1523 
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 1524 
 1525 
Figure 7—figure supplement 1 IMLECs broadly over-express multiple 1526 
families of pattern recognition receptors (PRRs) when compared with other 1527 
blood cells.  1528 
(A) Heat map showing the relative expression levels of genes encoding key 1529 
PRRs. TLRs, Toll-like receptors; NLR, Nod-like receptors; RLRs, RIG-I-like 1530 
receptors; ALRs, Aim2-like receptors. (B) mRNA levels of the indicated PPRs 1531 
genes were measured by q-PCR in  WBM cells from Ctrl mice and CD11b+ Gr-1- 1532 
BM IMLECs from cKO mice. n=3 for Ctrl WBM; n=5 for cKO BM IMLECs.  1533 
 1534 
Supplementary file 1 Transcript levels of CD markers analyzed from RNA-1535 
seq datasets. The FPKM values of 3 mice samples for cKO-IMLEC group (Rptor 1536 
cKO CD11b+Gr-1- BM IMLECs) and Ctrl-WBM group (Ctrl whole BM cells) are 1537 
shown. Fold change indicates the ratio of average FPKM values. 1538 
 1539 
Supplementary file 2 Expression levels of miRNAs targeting Myb in Raptor 1540 
Ctrl and cKO BM HSPCs. The normalized signal values of 3 mice samples for 1541 
cKO-HSPCs group and Ctrl-HSPCs group are shown. The microarray data have 1542 
been deposited to NCBI GEO database with accession number GSE64042 as 1543 
previously reported43. 1544 
 1545 
Supplementary file 3 The list of antibodies used for flow cytometry. 1546 
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 1547 
Supplementary file 4 Sequences of DNA primers used in PCR assays. 1548 
 1549 
 1550 
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